Displaying drugs 9101 - 9125 of 9162 in total
Dihydroquinidine barbiturate
Experimental
Tridolgosir
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
Fiboflapon
Investigational
Lucatumumab
Investigational
Meplazumab
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Tucidinostat
Investigational
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
APD668
APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.
Investigational
Adomiparin
Investigational
4-Methoxyamphetamine
Experimental
Illicit
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
ALGRX 1207
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Methoxyamine
Investigational
Alanosine
An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Investigational
Tin protoporphyrin IX
Investigational
BG-777
BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Investigational
Quisovalimab
Investigational
Lanoteplase
Investigational
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Pegpleranib
Investigational
Propentofylline
Investigational
Elsiglutide
Investigational
ACY001
Investigational
Teprenone
Experimental
Displaying drugs 9101 - 9125 of 9162 in total